GamaMabs Pharma

GamaMabs Pharma is a clinical-stage immuno-oncology company dedicated to developing optimized therapeutic antibodies for cancer treatment. Its lead program is GM102 (formerly known as 3C23K), a monoclonal antibody targeting the anti-Müllerian hormone receptor (AMHR2) in gynecological cancers, currently in Phase Ia/Ib. GM102 demonstrates enhanced tumor cell killing through its EMABling® glycoengineering technology, which activates immune system cells to destroy cancer cells.